Assess metabolic syndrome risk using ATP III and IDF criteria. Enter waist, blood pressure, glucose, triglycerides, and HDL to check all 5 diagnostic criteria.
Metabolic syndrome is a cluster of five interconnected cardiometabolic risk factors that increases the risk of cardiovascular disease (CVD), type 2 diabetes, stroke, and all-cause mortality. Roughly one-third of U.S. adults meet the diagnostic criteria, yet many are unaware. Identifying metabolic syndrome early allows targeted lifestyle interventions that may improve or even normalize several markers in some people.
This calculator evaluates your five core biomarkers against both the NCEP ATP III and International Diabetes Federation (IDF) diagnostic criteria: waist circumference (central obesity), triglycerides, HDL cholesterol, blood pressure, and fasting glucose. ATP III requires any 3 of 5 criteria; IDF requires central obesity plus any 2 additional criteria. The tool accounts for medication use (antihypertensives, statins, glucose-lowering drugs), which counts as meeting the respective criteria regardless of current lab values.
Beyond simple diagnosis, the calculator provides a risk score visualization, TG:HDL ratio (a rough proxy for insulin resistance), a side-by-side comparison of ATP III vs. IDF thresholds, and an evidence-based intervention table showing the expected impact of lifestyle changes. The 5–10% weight loss recommendation from the Diabetes Prevention Program (DPP) trial is one practical reference point because it substantially reduced diabetes incidence.
Metabolic syndrome is often silent, so the problem is easy to miss when each marker looks only mildly abnormal on its own. This calculator checks all five criteria against the two main diagnostic standards and keeps the TG:HDL ratio visible so the cardiometabolic pattern is easier to interpret as a whole.
ATP III Diagnosis: ≥3 of 5 criteria met. IDF Diagnosis: Central obesity (waist ≥94 cm men / ≥80 cm women) PLUS ≥2 of: TG ≥150, HDL <40 M/<50 F, BP ≥130/85, FG ≥100. TG:HDL Ratio = Triglycerides / HDL Cholesterol (insulin resistance proxy; >3.5 suggests risk).
Result: 5/5 criteria met — Metabolic Syndrome (ATP III & IDF positive)
This 42-inch waist male meets all five ATP III criteria: waist ≥40 in, TG ≥150, HDL <40, BP ≥130/85, FG ≥100. TG:HDL ratio of 4.3 suggests significant insulin resistance. Lifestyle intervention (5–10% weight loss, 150 min/wk exercise) is first-line treatment.
The common thread linking all five metabolic syndrome criteria is insulin resistance. When cells resist insulin's signal to absorb glucose, the pancreas compensates by producing more insulin (hyperinsulinemia). This excess insulin promotes: (1) central fat accumulation, (2) hepatic triglyceride overproduction, (3) reduced HDL production, (4) sodium retention and sympathetic nervous system activation (raising blood pressure), and (5) eventually beta-cell exhaustion and hyperglycemia. Treating insulin resistance — through exercise, weight loss, and dietary changes — addresses the root cause rather than individual symptoms.
Metabolic syndrome thresholds were developed primarily in European populations. Asian populations develop insulin resistance and visceral adiposity at lower waist circumferences — the IDF recommends ≥90 cm for Asian men (vs. 94 cm European). South Asian, Hispanic, and African American populations have higher metabolic syndrome prevalence at equivalent BMI levels, highlighting the importance of waist circumference over BMI as a screening tool.
Emerging evidence links metabolic syndrome to increased risk of colorectal, breast (postmenopausal), endometrial, liver, and pancreatic cancers. The mechanisms involve chronic hyperinsulinemia (insulin is a growth factor), chronic inflammation (elevated CRP, TNF-α, IL-6), and altered adipokine signaling. Cancer prevention is an additional reason to address metabolic syndrome aggressively.
Last updated:
This worksheet checks the entered waist circumference, blood pressure, fasting glucose, triglycerides, HDL, and medication status against ATP III and IDF metabolic syndrome criteria. It also exposes the TG:HDL ratio as a simple pattern marker and then summarizes which criteria are met.
The output is a screening worksheet, not a diagnosis. Clinical context, ethnicity-specific waist cutoffs, repeat labs, and medication history can all influence the interpretation.
Metabolic syndrome (formerly Syndrome X) is a cluster of five risk factors — central obesity, high triglycerides, low HDL, high blood pressure, and high fasting glucose — that occur together and dramatically increase the risk of heart disease, stroke, and type 2 diabetes. The pattern matters because the combined risk is higher than any single borderline marker on its own.
ATP III (American) requires any 3 of 5 criteria regardless of order. IDF (International) requires central obesity as mandatory, plus any 2 of the other 4. IDF uses tighter waist cutoffs (94 cm men, 80 cm women vs. 102/88 cm). IDF diagnoses more people globally.
Yes. The PREDIMED trial showed a Mediterranean diet resolved metabolic syndrome in 37% of participants at 2 years. The DPP trial showed 5–10% weight loss reduced diabetes risk by 58%. Exercise (150 min/wk) independently improves all five markers. Reversal is entirely possible with sustained lifestyle changes.
The triglyceride-to-HDL ratio is a simple, inexpensive proxy for insulin resistance and small dense LDL particles. A ratio >3.5 suggests insulin resistance; >5.0 indicates high cardiovascular risk. It is often a better predictor of heart disease than LDL cholesterol alone.
Yes, even meeting 1–2 criteria increases cardiometabolic risk above baseline. Metabolic syndrome exists on a continuum, not a binary threshold. Addressing borderline values now prevents progression. Think of it as an early warning system.
Yes. Pediatric metabolic syndrome affects ~10% of U.S. adolescents and up to 30% of obese children. Modified criteria with age-appropriate cutoffs are used. Childhood metabolic syndrome strongly predicts adult cardiovascular disease and type 2 diabetes.